Proactive Investors - Run By Investors For Investors

Redx Pharma inks option and licence agreement for NBTI programme

The drug developer has signed an option and licence agreement with Deinove, a biotech that develops high value drugs and other products from rare bacteria
petrie dish
The rise of super-bugs that are immune to traditional antibiotics is now generally regarded as a pressing threat

In line with its strategy to focus in on its cancer and fibrosis pipeline, Redx Pharma Plc (AIM:REDX) has found a prospective partner for its next-generation anti-biotics.

For the drug developer has signed an option and licence agreement with Deinove of France that effectively outsources its novel bacterial topoisomerase inhibitor (NBTI) programme.

READ: Redx Pharma to present poster at American Association for Cancer Research Annual meeting

The nuts and bolts of the deal are as follows: Deinove has a nine-month period to assess the NBTI portfolio for further development.

Option deal 

Redx will receive a “fee and a payment” once the option has been triggered. Financial details were not disclosed.

Deinove, a biotech that develops high value drugs and other products from rare bacteria, will begin immediately confirmatory and profiling work with the compounds in the RedX programme.

Researchers are hoping to find a drug candidate to combat multi-drug resistant Gram negative bacteria.

Rise of super-bugs

The rise of super-bugs that are immune to traditional antibiotics is now generally regarded as a pressing threat and certainly one that developed economies and the World Health Organisation are taking seriously.

RedX chairman Iain Ross said: "We are very pleased to have partnered our NBTI programme with Deinove, who are committed to the development of anti-infectives and whose team has a proven track record of bringing products to market.

“With their experience in this area, we hope that they can successfully progress our NBTI programme towards the clinic.

“We had previously indicated our commitment to progressing anti-infectives research through a collaboration in the near term and are delighted to be making this announcement on schedule."

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use